La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that
Deirdre Y. Gillespie, M.D., President and Chief Executive Officer, will
present on Tuesday, August 12, at 11:00 am Eastern Time during the
Canaccord Adams 28th Annual Global Growth
Conference. The conference will take place at The Intercontinental Hotel
in Boston. An audio web cast of the presentation will be available
through the Company’s Web site: http://www.ljpc.com.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is dedicated to improving and preserving
human life by developing innovative pharmaceutical products. The Company’s
leading product in development is Riquent®,
which is designed to treat lupus renal disease by preventing or delaying
renal flares. Lupus renal disease is a leading cause of sickness and
death in patients with lupus. The Company has also developed potential
small molecule drug candidates to treat various other autoimmune and
inflammatory conditions. The Company's common stock is traded on The
Nasdaq Global Market under the symbol LJPC. More information about the
Company is available on its Web site: http://www.ljpc.com.
This press release and the presentations may contain forward-looking
statements within the meaning of the federal securities laws. When used,
the words "anticipate,” "assume,” "believe,” "estimate,” "expect,” "intend,” "may,” "plan,” "project,” "result,” "should,” "will” and similar
expressions that do not relate solely to historical matters identify
forward-looking statements. Forward-looking statements are subject to
risks and uncertainties, both known and unknown and often beyond the
Company’s control, and are not guarantees of
future performance insofar as actual events or results may vary
materially from those anticipated. Factors that may cause such a
variance consist of, among others, those discussed from time to time in
the Company’s filings with the Securities and
Exchange Commission, including the risks described in "Risk
Factors” in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2007, and
specifically the Company’s ability to:
demonstrate sufficiently Riquent’s efficacy
and safety in clinical trials; obtain additional funding; manufacture
Riquent on an adequate scale for clinical use; or develop further and
commercialize Riquent successfully, either on its own or with a partner. The Company expressly disclaims any responsibility to update
forward-looking statements.
